FDA grants orphan status for Amarantus' eltoprazine to treat PD-LID

The US Food and Drug Administration (FDA) has granted orphan drug designation for Amarantus BioScience Holdings' (AMBS') eltoprazine to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news